Durect (DRRX)

[realfast95]

DURECT Corp (DRRX): Positive Signs For Posimir - HC Wainwright\

https://www.streetinsider.com/Analyst+Comments/DURECT+Corp+%28DRRX%29%3A+Positive+Signs+For+Posimir+-+HC+Wainwright/13039113.html

H.C. Wainwright analyst, Ed Arce, reiterated his Buy rating on shares of Durect Corp (NASDAQ: DRRX) after the company announced it has completed patient enrollment into its pivotal Phase 3 trial of Posimir, an investigational extended-release depot utilizing DURECT's patented SABER
technology intended to continuously deliver bupivacaine to the surgical site for continuous pain relief for up to three days post surgery. While the expected enrollment number for PERSIST was 264
patients, actual enrollment was higher, at 296 patients, as a result of rapid enrollment toward the end of the trial.

The analyst believes this has three important positive implications:

1) a higher enrollment number may indicate increased physician and patient interest in Posimir.

2) having significantly more patients strengthens the statistical robustness of PERSIST results.

3) at minimum, a higher enrollment will provide a higher patient count for the NDA safety database.

No change to the price target of $3.00